Proactive Investors - Run By Investors For Investors

Redx Pharma up as it confirms cancer drug clinical trial will re-start early next year

After discussions with the regulator, RXC004 will be administered at a lower initial dose
Redx Pharma up as it confirms cancer drug clinical trial will re-start early next year
Redx is developing a new generation of cancer drug called a porcupine inhibitor

Redx Pharma plc(LON:REDX) shares gained on Wednesday as the group confirmed it will restart early-stage clinical trials on its cancer drug after discussion with the regulator.

The phase I/IIa assessment of RXC004 was halted in March amid concerns the initial dosing was too high.

Crucially, there were no other 'off-target' side-effects, while the compound appeared to act in the way expected.

Following talks with the Medicines and Healthcare Regulatory Agency, work will restart early next year at a lower initial dose.

First-half results

The update was provided alongside first-half results, which showed Redx to be in a financially strong position with just over £10mln in the bank as at March 31.

The company, which recently unveiled senior AstraZeneca executive Lisa Anson  its new chief executive, has also managed to cut £7mln from costs on an annualised basis.

It meant that Redx's loss fell to £4.6mln in the six months from £10.7mln.

"I am pleased with the progress that Redx has made in the past six months," said chairman Iain Ross.  

"We have continued to advance our R&D programmes and achieved substantial cost savings across the business."

In mid-morning trading, Redx shares were 1.9% higher at 13.75p.

-- Adds share price --

 

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
1550762209_shutterstock_291998651.jpg
February 22 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use